Navigation Links
GEN Reports on Strategies to Overcome Blood-Brain Barrier
Date:2/5/2009

NEW ROCHELLE, N.Y., Feb. 5 /PRNewswire/ -- The blood-brain barrier (BBB) remains a major obstacle to the successful delivery of drugs to treat central nervous system (CNS) disorders, reports Genetic Engineering and Biotechnology News (GEN). Researchers are exploring a variety of approaches to preserve the ability of the BBB to block harmful and toxic substances from entering the brain and to permit the passage of effective medicines for the treatment of CNS diseases, according to the February 1 issue of GEN (http://www.genengnews.com/articles/chitem.aspx?aid=2778).

"The blood-brain barrier issue probably serves as the most significant roadblock to the treatment of central nervous system diseases," says John Sterling, Editor in Chief of GEN. "The key challenge is to treat people suffering from CNS disorders while trying to stay true to the physician's oath, 'First do no harm'."

One technology for enabling active transport of small molecule drugs across the BBB involves targeting endogenous nutrient transporters. These transporters are members of the solute carrier (SLC) transporter superfamily. Transport of small molecules across the BBB by these membrane proteins is known as carrier-mediated transport (CMT).

In order to design drugs that utilize CMT to cross the BBB, researchers modify their chemical structures so that they resemble nutrients that are transported across the BBB by specific SLCs. The prototypical drug that uses this strategy (which was developed long before mechanisms of CMT were known) is L-DOPA, the major current drug for Parkinson's disease. L-DOPA is used to replace dopamine that is lost due to degeneration of dopaminergic neurons in the substantia nigra of the brain.

Another major system that is used in normal mammalian physiology to enable needed molecules to cross the BBB is receptor-mediated transport (RMT). The brain uses RMT to transport proteins, peptides, and lipoproteins that are needed for brain function across the BBB. Examples of biomolecules that are transported into the brain via RMT include insulin, insulin-like growth factor (IGF), leptin, transferrin, and low-density lipoprotein (LDL).

In RMT, molecules in the circulation may bind to specific receptors on the luminal surface of brain capillaries (i.e., the surface that interfaces with the bloodstream). Upon binding, the receptor-ligand complex is internalized into the endothelial cell by a process called receptor-mediated endocytosis. The ligand may then be transported across the abluminal membrane of the endothelial cell (i.e., the membrane that interfaces with brain tissue) into the brain. This whole process is called receptor-mediated transcytosis.

Among the companies and academic centers covered in the GEN blood-brain barrier article are Pfizer, Lilly, Bristol-Myers Squibb, Otsuka, GlaxoSmithKline, Xenoport, ArmaGen, UCLA, Leiden University, and The Immune Disease Institute at Harvard Medical School.

For a copy of the February 1 issue of GEN, please call (914) 740-2122, or email: mebicovny@liebertpub.com

Genetic Engineering and Biotechnology News (www.genengnews.com), which is published 21 times a year by Mary Ann Liebert, Inc., is the most widely read biotechnology news magazine worldwide. It includes articles on Drug Discovery, Bioprocessing, OMICS, Biobusiness, and Clinical Research and Diagnostics.

Contact: John Sterling, Editor in Chief, Genetic Engineering and Biotechnology News, (914) 740-2196; mjsterling@genengnews.com


'/>"/>
SOURCE Genetic Engineering and Biotechnology News (GEN)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
2. Haemacure Reports Third Quarter 2007 Results
3. First-Ever List of the 5,000 Fastest-Growing Businesses Reports Total Revenue of $194.5 Billion
4. Consumer Reports Analysis: Drugs for Nerve Pain, Fibromyalgia Effective, But Not Always Best
5. MDS Reports Third Quarter 2007 Results
6. Allied Healthcare Reports Strong Fourth Quarter, Flat Net Income for Fiscal 2007 vs. 2006
7. AtriCure Reports First Human Implant of the Cosgrove-Gillinov Left Atrial Appendage Occlusion System
8. NMHC Reports Fourth Quarter and Fiscal Year 2007 Financial Results
9. Blue Cross and Blue Shield of Florida Reports Eighteenth Consecutive Year of Positive Performance
10. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
11. AdCare Health Systems, Inc. Reports Discontinuation of Definitive Merger Agreement with Family Home Health Services, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/26/2017)... ... May 26, 2017 , ... Boar’s Head Brand®, ... recipes for Memorial Day entertaining that are sure to satisfy your guests’ flavor ... sliced meats and cheeses featured in these refreshingly balanced recipes are packed with ...
(Date:5/26/2017)... , ... May 26, 2017 , ... Yisrayl Hawkins, Pastor ... publication this week that is focusing on the Peace Agreements being discussed by President ... East sprint in a race to try to speed up peace talks in the ...
(Date:5/26/2017)... ... May 26, 2017 , ... “When the Stars Lead Home”: a poignant ... of published author Laura Weigel Douglas, an avid reader who lives in the Pacific ... sometimes feels like Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year ...
(Date:5/26/2017)... ... ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack and the impact ... the creation of published author, Walter Hubbard, a retired wildlife and fisheries biologist and ... Walter. Walter and Jane have three adult children and a granddaughter. Walter ...
(Date:5/24/2017)... ... May 24, 2017 , ... Dr. Alan I. Benvenisty, MD ... New York City. He is known for his distinguished expertise and experience in the ... Benvenisty holds sub-specialty training in treating renovascular disease and aortic aneurysm . He ...
Breaking Medicine News(10 mins):
(Date:5/4/2017)... , May 4, 2017  Fortuna Fix Inc. (" ... to be the first to eliminate the need for embryonic ... cells to treat neurodegenerative diseases. Fortuna ... with Professor Michael Fehlings , MD, PhD; Father ... , MD, MPH; and Professor James Giordano , PhD. ...
(Date:5/4/2017)... DIEGO , May 4, 2017  The American ... and Scientific Meeting— OBP Medical , a leading global ... the launch of a new extra-small size and first-in-market ... ER-SPEC vaginal specula. Already available in small, medium, ... makes OBP Medical,s line of single-use lighted specula the ...
(Date:5/4/2017)...   BioLife Solutions , Inc. (NASDAQ: ... proprietary clinical grade hypothermic storage and ... announced that the Company,s first quarter 2017 financial results ... 11, 2017, and that the Company will host a ... that afternoon. Management will provide an overview of the ...
Breaking Medicine Technology: